These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 9833743)

  • 1. Factors associated with HIV-infected patients' recognition and use of HIV medications.
    Jeffe DB; Meredith KL; Mundy LM; Fraser VJ
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec; 19(4):350-60. PubMed ID: 9833743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sources influencing patients in their HIV medication decisions.
    Meredith KL; Jeffe DB; Mundy LM; Fraser VJ
    Health Educ Behav; 2001 Feb; 28(1):40-50. PubMed ID: 11213141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity.
    Kumar PN; Rodriguez-French A; Thompson MA; Tashima KT; Averitt D; Wannamaker PG; Williams VC; Shaefer MS; Pakes GE; Pappa KA;
    HIV Med; 2006 Mar; 7(2):85-98. PubMed ID: 16420253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuation of postpartum antiretroviral therapy in a cohort of women infected with human immunodeficiency virus.
    Tedaldi E; Willard S; Gilmore J; Holdsworth C; Dix-Lassiter S; Axelrod P
    J Assoc Nurses AIDS Care; 2002; 13(1):60-5. PubMed ID: 11828860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial.
    Bussmann H; Wester CW; Thomas A; Novitsky V; Okezie R; Muzenda T; Gaolathe T; Ndwapi N; Mawoko N; Widenfelt E; Moyo S; Musonda R; Mine M; Makhema J; Moffat H; Essex M; Degruttola V; Marlink RG
    J Acquir Immune Defic Syndr; 2009 May; 51(1):37-46. PubMed ID: 19282782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir trial).
    Joly V; Flandre P; Meiffredy V; Brun-Vezinet F; Gastaut JA; Goujard C; Remy G; Descamps D; Ruffault A; Certain A; Aboulker JP; Yeni P;
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1906-13. PubMed ID: 12019107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study.
    Carr A; Chuah J; Hudson J; French M; Hoy J; Law M; Sayer D; Emery S; Cooper DA
    AIDS; 2000 Jun; 14(9):1171-80. PubMed ID: 10894281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study.
    French M; Amin J; Roth N; Carr A; Law M; Emery S; Drummond F; Cooper D;
    HIV Clin Trials; 2002; 3(3):177-85. PubMed ID: 12032876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
    Eron JJ; Murphy RL; Peterson D; Pottage J; Parenti DM; Jemsek J; Swindells S; Sepulveda G; Bellos N; Rashbaum BC; Esinhart J; Schoellkopf N; Grosso R; Stevens M
    AIDS; 2000 Jul; 14(11):1601-10. PubMed ID: 10983647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.
    Albrecht MA; Hughes MD; Liou SH; Katzenstein DA; Murphy R; Balfour HH; Para MF; Valdez H; Hammer SM;
    AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1337-44. PubMed ID: 11018853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acceptance and adherence with antiretroviral therapy among HIV-infected women in a correctional facility.
    Mostashari F; Riley E; Selwyn PA; Altice FL
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Aug; 18(4):341-8. PubMed ID: 9704939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).
    Squires KE; Gulick R; Tebas P; Santana J; Mulanovich V; Clark R; Yangco B; Marlowe SI; Wright D; Cohen C; Cooley T; Mauney J; Uffelman K; Schoellkopf N; Grosso R; Stevens M
    AIDS; 2000 Jul; 14(11):1591-600. PubMed ID: 10983646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perceived compliance with AZT dosing among a sample of African-American drug users.
    Williams M; Bowen A; Ross M; Freeman R; Elwood W
    Int J STD AIDS; 2000 Jan; 11(1):57-63. PubMed ID: 10667903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined analysis of two-year follow-up from two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitor backbones for previously untreated HIV-1 infection: OzCombo 1 and 2.
    Amin J; Moore A; Carr A; French MA; Law M; Emery S; Cooper DA;
    HIV Clin Trials; 2003; 4(4):252-61. PubMed ID: 12916011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection.
    Ungsedhapand C; Srasuebkul P; Cardiello P; Ruxrungtham K; Ratanasuwan W; Kroon ED; Tongtalung M; Juengprasert N; Ubolyam S; Siangphoe U; Emery S; Lange JM; Cooper DA; Phanuphak P;
    J Acquir Immune Defic Syndr; 2004 Jun; 36(2):693-701. PubMed ID: 15167288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virological and immunological responses to once-daily dosing of didanosine in combination with stavudine. AI454-143 Team.
    Mobley JE; Pollard RB; Schrader S; Adler MH; Kelleher T; McLaren C
    AIDS; 1999 Jul; 13(11):F87-93. PubMed ID: 10449279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disparities in outcomes for African American and Latino subjects in the Flexible Initial Retrovirus Suppressive Therapies (FIRST) trial.
    Giordano TP; Bartsch G; Zhang Y; Tedaldi E; Absalon J; Mannheimer S; Thomas A; MacArthur RD
    AIDS Patient Care STDS; 2010 May; 24(5):287-95. PubMed ID: 20438378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
    García F; Romeu J; Grau I; Sambeat MA; Dalmau D; Knobel H; Gomez-Sirvent JL; Arrizabalaga J; Cruceta A; Clotet BG; Podzamczer D; Pumarola T; Gallart T; O'Brien WA; Miró JM; Gatell JM
    AIDS; 1999 Dec; 13(17):2377-88. PubMed ID: 10597779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ddI and d4T plus protease inhibitors.
    GMHC Treat Issues; 1996 Nov; 10(11):8-9. PubMed ID: 11364012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.